| Name | Aurora At Home |
|---|---|
| Location | 11333 W National Ave, Milwaukee, Wisconsin |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 527001 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 53002, 53003, 53004, 53005, 53006, 53007, 53010, 53012, 53017, 53018, 53021, 53022, 53024, 53027, 53029, 53032, 53033, 53034, 53035, 53036, 53037, 53038, 53039, 53040, 53045, 53046, 53047, 53048, 53050, 53051, 53052, 53058, 53059, 53060, 53064, 53066, 53069, 53072, 53074, 53076, 53078, 53080, 53081, 53086, 53089, 53090, 53091, 53092, 53094, 53095, 53097, 53098, 53103, 53104, 53105, 53108, 53110, 53114, 53115, 53118, 53119, 53120, 53121, 53122, 53125, 53126, 53128, 53129, 53130, 53132, 53137, 53138, 53139, 53140, 53142, 53143, 53144, 53146, 53147, 53148, 53149, 53150, 53151, 53153, 53154, 53156, 53157, 53158, 53159, 53167, 53168, 53170, 53171, 53172, 53176, 53177, 53178, 53179, 53181, 53182, 53183, 53184, 53185, 53186, 53188, 53189, 53190, 53191, 53192, 53194, 53195, 53202, 53203, 53204, 53205, 53206, 53207, 53208, 53209, 53210, 53211, 53212, 53213, 53214, 53215, 53216, 53217, 53218, 53219, 53220, 53221, 53222, 53223, 53224, 53225, 53226, 53227, 53228, 53233, 53235, 53402, 53403, 53404, 53405, 53406, 53557, 53585, 54104 |
| NPI Number | 1134255037 |
| Organization Name | VISITING NURSE ASSOCIATION OF WISCONSIN, INC. |
| Doing Business As | AURORA AT HOME |
| Address | 11333 W National Ave, West Allis, WI 53227 |
| Phone Number | 414-327-2295 |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
| Quality Rating: |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 87.9 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.5 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.7 | 99.6 |
| How often the home health team checked patients for depression | 99.2 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 83.4 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 94.5 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.2 | 96.4 |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 82.4 | 79.6 |
| How often patients got better at getting in and out of bed | 83.8 | 81.1 |
| How often patients got better at bathing | 83.5 | 82.3 |
| How often patients’ breathing improved | 88 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 89.6 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 77.5 | 75 |
| How often home health patients had to be admitted to the hospital | 13.8 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 15.7 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 98.7 | 94 |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
The patient survey data of Aurora At Home is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 90 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 86 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 87 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 81 | 78 |
News Archive
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
CredenceHealth, a provider of real-time clinical intelligence for hospitals and health plans, announced today that OhioHealth, an 8-hospital, 2000+bed, not-for-profit hospital system in Columbus, Ohio, has selected CredenceHealth for its latest real-time clinical surveillance initiative.
Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
The current flu season is on track to be one of the most severe in years, according to new data from the CDC.
Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.
› Verified 2 days ago
Aurora At Home Location: 11333 W National Ave, Milwaukee, Wisconsin 53227 Ratings: Phone: (414) 327-2295 | |
Horizon Home Care And Hospice Location: 11400 W Lake Park Drive, Milwaukee, Wisconsin 53224 Ratings: Phone: (414) 365-8300 | |
Metro Home Health Service Location: 6014 W Congress St, Milwaukee, Wisconsin 53218 Ratings: NA Phone: (414) 464-4490 | |
Laabs Home Health Care Location: 619 N 35th St, Milwaukee, Wisconsin 53208 Ratings: NA Phone: (414) 342-7442 | |
Ascension At Home Location: 3070 North 51st St Ste 406, Milwaukee, Wisconsin 53210 Ratings: Phone: (414) 455-9500 | |
Heartland Home Health Care And Hospice Location: 1233 North Mayfair Rd Suite 100, Milwaukee, Wisconsin 53226 Ratings: Phone: (414) 944-2000 |